MT1
MT1
Melanotan I (afamelanotide) is a selective MC1R agonist that stimulates the body's natural melanogenesis pathway, increasing skin pigmentation by activating eumelanin synthesis in melanocytes. A Phase 3 human trial published in the New England Journal of Medicine demonstrated a six-fold increase in sun exposure tolerance alongside significant quality-of-life improvements. This evidence base supported full FDA and EMA pharmaceutical approval of afamelanotide as Scenesse — the first licensed treatment for erythropoietic protoporphyria.
Supplied as research-grade lyophilised peptide. Requires reconstitution with bacteriostatic water prior to use. For research purposes only.
Research Stack Builder
Build Your Research Stack
Curated combinations based on what researchers actually stack — backed by published data, priced to save.
Stack with MT1
Why researchers stack these
- 01UV protection + structural skin integrity
- 02Antioxidant shield during melanogenesis
- 03DNA repair to address UV-related cell damage
Full research context
MT1 drives eumelanin synthesis to create natural UV photoprotection — the mechanism behind its FDA and EMA approval. GHK-Cu adds structural skin support: collagen synthesis, extracellular matrix repair, and the gene modulation that improves overall skin integrity beyond pigmentation alone. Glutathione reduces UV-induced oxidative stress and modulates tyrosinase activity. NAD+ addresses the DNA repair demands that UV exposure creates — activating PARP-mediated repair mechanisms that are essential for skin cell longevity under photoprotection research protocols.
Recovery & Repair Protocol
The most studied peptide combination for tissue repair, injury recovery & musculoskeletal healing
Why researchers stack these
- 01Non-competing structural repair pathways
- 02BPC-157 angiogenesis + TB-500 satellite cell activation
- 03GHK-Cu adds the extracellular matrix layer both lack
Full research context
BPC-157 and TB-500 are the two most frequently co-researched repair peptides in published literature, acting through complementary mechanisms — BPC-157 via nitric oxide pathways and angiogenesis, TB-500 via actin-sequestering and satellite cell activation. GHK-Cu rounds out the stack by supporting collagen synthesis and the extracellular matrix that both compounds do not directly address, while reducing the oxidative load that slows tissue recovery.
Metabolic & Body Recomposition
Most popular Peptide Pal stack — two non-competing fat loss axes with skin integrity support
Why researchers stack these
- 01GLP-1 triple agonism + GH axis — two distinct fat loss pathways
- 02Skin integrity preserved throughout recomposition
- 03Most purchased together on Peptide Pal
Full research context
Retatrutide and Tesamorelin address body composition through two non-competing mechanisms. Retatrutide's triple receptor agonism drives broad metabolic improvement and appetite regulation; Tesamorelin is FDA-approved for visceral adipose reduction through the growth hormone axis — a distinct mechanism. GHK-Cu supports skin integrity during recomposition; rapid fat loss without collagen support produces visible skin laxity that is far harder to address after the fact.
Cognitive Performance Stack
Neuropeptides studied for synergistic cognitive enhancement, focus & stress resilience — no sedation
Why researchers stack these
- 01BDNF stimulation balanced by GABA modulation
- 02Focus without anxiety — three non-competing pathways
- 03NAD+ fuels the neuronal energy demand
Full research context
Semax and Selank are registered pharmaceuticals with distinct mechanisms. Semax drives BDNF upregulation and cortical processing speed; Selank reduces the stress-induced cognitive interference that can blunt that effect, without sedation or dependency. NAD+ provides the cellular energy substrate that enhanced neuronal activity demands — researchers consistently report that this combination delivers balanced cognitive performance that neither compound achieves alone.
Skin & Glow Protocol
Collagen synthesis, antioxidant protection & melanin research in one comprehensive skin stack
Why researchers stack these
- 01Collagen, antioxidant & pigmentation — three skin pillars
- 02Tyrosinase inhibition counterbalances MC1R agonism for pathway research
- 03Structural integrity maintained alongside brightening
Full research context
GHK-Cu stimulates collagen synthesis and modulates over 4,000 genes involved in skin repair and inflammatory control — addressing the structural layer. Glutathione reduces oxidative stress and inhibits tyrosinase, producing measurable skin brightening with 30–35% tissue GSH increases confirmed in human RCTs. MT2 drives eumelanin synthesis via MC1R agonism, and researchers frequently combine it with Glutathione to study the interplay between melanocortin-driven pigmentation and tyrosinase inhibition simultaneously. Together these three represent the most comprehensive skin research protocol available.
Cellular Longevity Protocol
Three compounds that decline together with age — combined restoration for mitochondrial & cellular health
Why researchers stack these
- 01All three decline together with age — parallel restoration
- 02Mitochondrial energy, AMPK signalling & antioxidant protection
- 03Most complete cellular longevity protocol available
Full research context
NAD+, MOTS-c, and glutathione all decline measurably with age through parallel but distinct pathways. NAD+ restores sirtuin and PARP function essential for mitochondrial biogenesis and DNA repair — declining up to 50% by age 60. MOTS-c is the mitochondria-derived peptide that activates AMPK signalling and declines alongside NAD+; their combined restoration is the most researched longevity intervention. Glutathione provides the antioxidant protection that prevents cellular damage during the heightened metabolic activity that NAD+ and MOTS-c restoration drives — completing what researchers describe as the foundational cellular longevity triad.
Research & Studies
Peer-reviewed research supporting MT1
Afamelanotide Phase 3: Six-Fold Increase in Sun Exposure Tolerance in Human Trial — Now FDA Approved
A Phase 3 randomised controlled trial in 74 patients with erythropoietic protoporphyria (EPP) demonstrated that afamelanotide produced a median six-fold increase in the duration of direct sunlight exposure tolerated versus placebo, with significant reductions in phototoxic pain and large improvements in quality-of-life scores. The mechanism is potent stimulation of eumelanin synthesis in human skin, providing a physical UV barrier through natural pigmentation. This robust human trial evidence supported regulatory approval by the EMA (2014) and FDA (2019) of afamelanotide as Scenesse — the first approved treatment for EPP.
Melanotan I Reduces Phototoxic Episodes in Erythropoietic Protoporphyria Patients
Minder et al. demonstrated in a human study that Melanotan I significantly increased skin pigmentation and reduced the frequency and severity of phototoxic episodes in patients with erythropoietic protoporphyria. Participants treated with MT1 showed measurable increases in melanin index and a reduction in cumulative phototoxic events during the outdoor season compared to placebo, with the melanogenic effect providing a natural UV-protective barrier. Patient-reported outcomes showed significant improvements in sun avoidance behaviour, quality of life, and ability to participate in outdoor activities.